UroGen Pharma Ltd.
URGN$675M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaRA'ANANA287 employees
Drugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Oct 15, 2026
20wMarket Overview
Stock performance and key metrics
URGN News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
UGN-101 instillations
Carcinoma, Transitional Cell
UGN-102
Bladder Cancer
UGN-104
Upper Urinary Tract Urothelial Carcinoma
UGN-103
Bladder Cancer
120 mg MMC in 90ml gel
Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UGN-101 instillations | Phase 3 | Carcinoma, Transitional Cell | - | - |
UGN-102 | Phase 3 | Bladder Cancer | - | - |
UGN-104 | Phase 3 | Upper Urinary Tract Urothelial Carcinoma | - | - |
UGN-103 | Phase 3 | Bladder Cancer | - | - |
120 mg MMC in 90ml gel | Phase 2 | Bladder Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply